Finn Søndergaard – CEO, Intsel Chimos, France
Finn Søndergaard, CEO of Intsel Chimos, shares the motivation behind the company’s two recent acquisitions of Diverchim and Centre Lab, and the new strategic opportunities to expand as a full-service…
Intsel Chimos is an independent French laboratory with a long history of expertise in the import of medicines for patients in a therapeutic impasse and a partner of choice for hospitals. In 2010 and 2011, Intsel Chimos obtained orphan drug status from the EMA and the FDA respectively for a molecule intended for the treatment of gliomas (brain tumours), which marks the beginning of their transformation into a promising biotech player in France.
Contact
162 Bureaux de la Colline • 92213 SAINT CLOUD CEDEX • France
Tel: 01 49 11 66 80
Web: intselchimos.com
Email: contact@intselchimos.com
Finn Søndergaard, CEO of Intsel Chimos, shares the motivation behind the company’s two recent acquisitions of Diverchim and Centre Lab, and the new strategic opportunities to expand as a full-service…
Mr. Finn Søndergaard, CEO of Intsel Chimos, an independent French laboratory with a long history of expertise in the import of medicines for patients in a therapeutic impasse, highlights Intsel…
Novasep is the largest contract manufacturer for the pharmaceuticals and fine chemicals industries in France. Michel Spagnol, the company’s chairman and CEO, highlights recent reorganization and “back to basics” strategy…
Lyon provides companies with a flamboyant and collaborative environment to develop. Bruno Masurel, Head of the International Division of the local Chamber of Commerce talks about the advantages the region…
Erin Gainer, the CEO of HRA Pharma, reveals how the company has significantly grown its business in the fields of women’s health and endocrinology over the past decade to become…
Pascal Brossard, the Managing Director of Zambon France and President of Afipa (Association for the French self-medication medicines industry), reveals why he is confident that the self-medication market in France…
The president of Daiichi Sankyo France discusses the affiliate’s positioning and future strategy, the challenges for an international pharmaceutical company in France but also why the many strengths of France…
The CEO of Onxeo, recently formed through the merger of the French BioAlliance Pharma and the Danish Topotarget, discusses its strategic turning decision to focus on orphan oncology, its promising…
Patrick Choay discusses his first foray into the pharmaceutical business world, talks about the highlights of his long and interesting career, his balanced partnership strategy for the Choay Group and…
Marc-Antoine Lucchini, the president-general manager of Sanofi France, talks about their unprecedented number of new molecules and innovations soon to be launched. He also explains the need to focus on the…
Aurélien Chaufour reveals how Anjac Health and Beauty has developed with a focus on innovation and industrial know-how since its creation in 2008 and how he today has four companies…
The CEO of Medicen Paris Region, the biopharma cluster for the Paris region, discusses her vision to develop a world-class cluster and act as a catalyst for innovation; her international…
Théa’s Jean-Frederic Chibret reveals how as a company focused purely on ophthalmology, they have the expertise to focus on niche areas that big pharma companies neglect; how they are the third…
Mr Truelle, the CEO of CDM Lavoisier, a company specialized in the pharmaceutical manufacturing of injectable solutions, reveals that one third of the French population could receive one of the…
See our Cookie Privacy Policy Here
